Apotex Sues FDA Over Gabapentin ANDAs, Says Purepac Exclusivity Has Run
Executive Summary
Apotex is suing FDA for immediate approval of its ANDA for a generic version of Pfizer's Neurontin
You may also be interested in...
FDA Generic “Shared” Exclusivity Policy Needs Judicial Clarity, Troy Says
FDA's patent-based approach to awarding generic marketing exclusivity is the only remaining issue of legal uncertainty under the original Waxman/Hatch framework, former FDA Chief Counsel Dan Troy said
FDA Generic “Shared” Exclusivity Policy Needs Judicial Clarity, Troy Says
FDA's patent-based approach to awarding generic marketing exclusivity is the only remaining issue of legal uncertainty under the original Waxman/Hatch framework, former FDA Chief Counsel Dan Troy said
Teva, Ivax Move Closer To Marketing Generic Gabapentin
Teva and Ivax are moving into position to consider "at risk" launches of generic gabapentin (Pfizer's Neurontin)